Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy (Nephrology Dialysis Transplantation (2008) DOI: 10.1093/ndt/gfm631);Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 927-933

  Zhou, Huali ^a   Tan, Kathryn C B ^a   Shiu, Sammy W M ^a   Wong, Ying ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced glycation end products; Cholesterol efflux; Diabetic nephropathy; HDL; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; POLYCLONAL ANTISERUM; RIBONUCLEASE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RABBIT; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED;

EID: 42449126292     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn214     Document Type: Erratum

References (22)

1. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
2. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146
3. Vlassara H, Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 2004; 5: 181-188
4. Chiarelli F, de Martino M, Mezzetti A et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-491
5. Tan KC, Chow WS, Tam S et al. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27: 223-228
6. Papanastasiou P, Grass L, Rodela H et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216-222
7. Dolhofer-Bliesener R, Lechner B, Gerbitz KD. Possible significance of advanced glycation end products in serumin end-stage renal disease and in late complications of diabetes. Eur J Clin Chem Clin Biochem 1996; 34: 355-361
8. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497
9. Gugliucci A, Mehlhaff K, Kinugasa E et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clinica Chimica Acta 2007; 377: 213-220
10. Ohgami N, Nagai R, Miyazaki A et al. Scavenger receptor class B type 1-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276: 13348-13355
11. Syvanne M, Castro G, Dengremont et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with of without coronary disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipids transfer protein. Atherosclerosis 1996; 127: 245-253
12. Tan KCB, Chow WS, Lam J et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-382
13. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23: 2083-2089
14. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63: 945-956
15. Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation ofmildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508
16. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694
17. Nobecourt E, Jacqueminet S, Hansel B et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005; 48: 529-538
18. Tan KCB, Chow WS, Lam JCM et al. Advanced glycation end products in non-diabetic patients with obstructive sleep apnea. Sleep 2006; 29: 329-333
19. Negrean M, Stirban A, Stratmann B et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-1243
20. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27
21. Van Eck M, Pennings M, Hoekstra M et al. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005; 16: 307-315
22. Isoda K, Folco EJ, Shimizu K, Libby P. AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 2007; 192: 298-304